The FDA clearance for NKGen Biotech's Investigational New Drug application is a significant regulatory milestone that could potentially boost investor confidence and the stock price of the company, if it is indeed associated with the ticker NKGN. The clearance allows the company to proceed with clinical trials for its SNK01 NK cell therapy, which could potentially lead to a new treatment option for Alzheimer's disease, a condition with significant unmet medical need.